STOCKHOLM, Aug. 8, 2019 /PRNewswire/ -- The data
generated from a unique single sequence on the
Siemens Healthineers MRI system
and SyMRI software provide quantitative MRI, tissue
specific parametric maps (R1, T1, R2, T2 and PD), multiple
contrast-weighted images and tissue volumes. This supports a faster
scan time while providing more information to the
clinician.
The SyMRI NEURO package is the first on the
market to include measurements and segmentation of
myelin-correlated volumes. Quantification of myelin may be useful
to monitor patients with neurodegenerative disorders such as
multiple sclerosis and dementia. This biomarker could also be of
value in the developing pediatric brain or in psychological
disorders such as autism, attention deficit disorder, and
schizophrenia.
"Siemens Healthineers can now also offer SyMRI as
a part of the syngo.via platform in the clinical
practice to the US market," says Isabelle
Hachette, Global Account Manager
at SyntheticMR AB. "We strive to support a faster
workflow and provide objective decision support to radiologists,
and we are now able to work towards this goal together
with Siemens Healthineers syngo.via team in
the US market."
"Through our partnership with SyntheticMR, we are further
transforming syngo.via into an independent
advanced visualization platform," says Oliver Klinkow, CRM Manager at Syngo. "We want
to empower our users to autonomously expand their clinical
capabilities with innovative solutions from a multitude of
international vendors."
The tse_mdme sequence is available on Siemens
Healthineers' MAGNETOM Vida with software version syngo MR XA11B
and on all other systems with future XA software
versions. syngo.via users can autonomously download
the SyMRI software trial from the Siemens
Healthineers Digital Marketplace and use it immediately –
integrated with their syngo.via. SyMRI is
also available as a stand-alone software version.
SyntheticMR AB develops and markets
innovative software solutions for Magnetic Resonance Imaging
(MRI). SyntheticMR AB product SyMRI® delivers
multiple contrast images and quantitative data from a single
6-minute scan – to improve patient throughput and objective
decision support for clinicians. SyMRI is CE-marked and
FDA 510(k) cleared. SyMRI is a registered trademark in
Europe and in the
USA. SyntheticMR is listed on the Spotlight Stock Market
in Stockholm, Sweden. For
additional information, please
visit www.syntheticmr.com.
Siemens Healthineers enables healthcare
providers worldwide to increase value by empowering them on their
journey towards expanding precision medicine, transforming care
delivery, improving patient experience and digitalizing healthcare.
A leader in medical technology, Siemens Healthineers is constantly
innovating its portfolio of products and services in its core areas
of diagnostic and therapeutic imaging and in laboratory diagnostics
and molecular medicine. Siemens Healthineers is also actively
developing its digital health services and enterprise services.In
fiscal 2018, which ended on September 30,
2018, Siemens Healthineers generated revenue of €13.4
billion and adjusted profit of €2.3 billion and has about 50,000
employees worldwide. Further information is available
at www.siemens-healthineers.com.
For more information please contact:
Isabelle Hachette
+46-708-73-53-69
Global Account Manager
SyntheticMR AB
or
Fredrik Jeppsson
CFO and Head of Investor relations
+46-72-303-1339
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/syntheticmr-ab/r/the-symri--neuro-software-from-syntheticmr-ab-is-now-available-on-syngo-via-open-apps-from-siemens-h,c2875837
The following files are available for download:
|
https://mb.cision.com/Main/11663/2875837/1087063.pdf
|
Read as
PDF.
|
View original
content:http://www.prnewswire.com/news-releases/the-symri-neuro-software-from-syntheticmr-ab-is-now-available-on-syngovia-open-apps-from-siemens-healthineers-in-the-usa-300898753.html
SOURCE SyntheticMR AB
